乳腺癌相关分子标记物研究进展  

Advances in molecular markers of breast cancer

作　　者：尤文叶 徐小洁[2] 叶棋浓[2] 李瑛[1] 杨俊兰[1] YOU Wenye XU Xiaojie YE Qinong LI Ying YANG Junlan(Department of Medical Oncology, Chinese PLA General Hospital, Beijing 100853, China Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Beijing 100850, China)

机构地区：[1]解放军总医院肿瘤内一科,北京100853 [2]军事医学科学院生物工程研究所,北京100850

出　　处：《解放军医学院学报》2016年第11期1200-1203,共4页Academic Journal of Chinese PLA Medical School

基　　金：国家自然科学基金(31100604);吴阶平基金(wjp-lc-11037);北京市科技新星计划(Z141102001814055);北京市自然科学基金(7132155);军事医学科学院创新基金转化医学项目(ZHYX003)~~

摘　　要：分子标记物对于疾病诊断、评估预后和预测疗效有其独特的优势,也是乳腺癌领域研究的热点。目前除了已经明确与乳腺癌密切相关的分子标记物ER、PR和HER2外,还发现许多新的分子标记物,包括受体类分子如表皮生长因子受体、血管内皮生长因子、Ki67、雄激素受体等,PI3K/AKT/m TOR信号通路,以及其他一些新型分子如聚腺苷二磷酸核糖聚合酶1、长链非编码RNA等。随着精准医学时代的到来,乳腺癌相关分子标记物的研究对于乳腺癌的个体化治疗具有重要的指导意义。Molecular markers have unique advantages on disease diagnosis, prediction of prognosis and assessment of therapeutic reactions, and it also becomes a hot topic in the area of breast cancer. Except for the well-known breast cancer biomarkers ER, PR and HER2, in recent years, many potential biomarkers for breast cancer have been found, including epidermal growth factor receptor（EGFR）, vascular endothelial growth factor（VEGF）, Ki67, androgen receptor（AR）, PI3K/AKT/m TOR signaling pathway, poly ADP- ribose polymerase 1（PARP-1）, as well as long chain noncoding RNA（lnc RNAs）. With the approaching of precision medicine, molecular markers of breast cancer shows important guiding significance for personalised therapy.

关 键 词：乳腺癌 分子标记物 肿瘤诊断 

分 类 号：R735.9[医药卫生—肿瘤]